｜2025年6月18日星期三 | NO.1 杭州住房公积金个人账户可直付购房首付款 6月17日，浙江省直公积金中心提取住房公积金直付购房首付款已正式上线。在杭州市区购买新建商品 房或二手房，都可用公积金个人账户余额直付首付款。其中，购买杭州市区新建商品房可通过"浙里 办"线上办理直付提取。同时，杭州市城投集团旗下安居宁巢携手省直公积金管理中心，推出全省首 个"省直公积金直付房租"服务，加大住房公积金对缴存人在租赁住房方面的支持力度。 点评：此举极大便利购房者，减轻资金筹备压力，提升购房支付灵活性。结合此前支持保障性住房提取 公积金政策，进一步发挥公积金保障作用，体现对住房消费支持，助力缓解住房难题，推动房地产市场 健康发展。 NO.2 温州购买二手住房可提取公积金支付首付款 点评：这旨在剥离中交地产的重资产、聚焦轻资产业务，契合行业转型趋势。公司高负债下，此举可优 化资产结构、降低偿债压力、增强盈利能力，为战略转型奠定基础，助力公司可持续发展。 点评：该政策能有效减轻购房者资金压力，激发二手房市场活力。允许购房人及其亲属提取，扩大受益 群体，提升公积金使用效率，为缴存职工家庭刚性和改善性住房需求提供有力支持， ...

*ST中地：拟1元转让房地产开发业务相关资产及负债 智通财经6月16日电，*ST中地(000736.SZ)发布重大资产出售报告书草案，公司拟将持有的房地产开发 业务相关资产及负债转让至控股股东中交房地产集团有限公司，交易价格为1元。此次交易构成重大资 产重组及关联交易。未来上市公司将聚焦于物业服务和资产管理与运营等稳定性强，有利于上市公司增 强盈利能力的轻资产业务，实现战略转型及高质量发展。 ...

作者 胡群 地方中小银行资本补充行动再次提速。 6月14日，苏农银行发布公告，宣布因2018年发行的可转债转股及2024年度资本公积转增股本，公司注册资本拟由18.03亿元增至20.19亿元。该议案尚需股东 大会审议及监管机构核准后生效。 这一消息并非孤例。6月9日晚间，在港上市的泸州银行公告称，该行将于月底召开年度股东大会，其中将审议拟根据特别授权非公开发行不超过10亿股新H 股的议案。此外，湖北银行等也处于增资扩股或上市排队过程中的关键节点。 除此之外，目前已有吉林银行、浙江泰隆银行、天津农商银行等多家银行通过发行二级资本工具补充资本。如西安银行6月13日在中国货币网发布公告称， 将发行20亿元二级资本债券。这已是西安银行2025年第二期二级资本债券，今年4月份，西安银行已发行20亿元二级资本债券。 资本承压与补血需求 中国银行业已进入一个较长的低利率周期。当前银行净息差已经处于历史低位，且仍在不断收窄。银行营收普遍高度依赖利息收入，如果收入结构不做出调 整，未来绝大多数银行将无法保持当前营收增长速度和盈利水平。同时由于房地产市场和地方政府债问题，企业和个人客户违约率上升也将使银行的资产质 量进一步承压。 ...

| 标的公司 | 交易对方 | | --- | --- | | Silex Microsystems AB | Bure Equity AB、Creades AB (publ)等 | | | 比名交易对友 小企号 · 芯榜 | 出售 瑞典Silex，押注北京晶圆厂 6 月 13 日，赛微电子宣布拟以 23.75 亿瑞典克朗（约合 17.83 亿元人民币）向 Bure、 Creades 等七方转让瑞典 Silex 45.24% 股份，交易后不再控股该公司，但保留参股股份 及 2 名董事席位。赛微电子称，因国际地缘政治环境复杂，瑞典 Silex 不确定性增加，为 维护公司利益决定出售其控制权。 交易完成后， 赛微电子 公司将重点发展北京 MEMS 晶圆工厂，其已掌握多项核心技术， 获专利 25 项、申请中 107 项，导入超 40 家客户。此次交易还将让公司获得可观资金， 用于寻找新投资并购机会。该交易是赛微电子审慎研究后的战略选择，既能为瑞典 Silex 谋 求更稳定经营环境，也助力公司实现战略转型及国内 MEMS 产业自主发展。 赛微电子出售瑞典 Silex 控股权要点 1. 交易核心 ：2025 年 6 月 ...

一、本报告是联合资信基于评级方法和评级程序得出的截至发表之日的 独立意见陈述，未受任何机构或个人影响。评级结论及相关分析为联合资信 基于相关信息和资料对评级对象所发表的前瞻性观点，而非对评级对象的事 实陈述或鉴证意见。联合资信有充分理由保证所出具的评级报告遵循了真 实、客观、公正的原则。鉴于信用评级工作特性及受客观条件影响，本报告 在资料信息获取、评级方法与模型、未来事项预测评估等方面存在局限性。 中交地产股份有限公司 www.lhratings.com 联合〔2025〕4326 号 联合资信评估股份有限公司通过对中交地产股份有限公司主体 及其相关债券的信用状况进行跟踪分析和评估，确定维持中交地产 股份有限公司主体长期信用等级为 AA+，维持"21 中交债"信用等 级为 AAA，评级展望为稳定。 特此公告 联合资信评估股份有限公司 $$\begin{array}{r}{{\exists\mathbb{H}}\&\oplus\mathbb{H}:}\\ {{\underline{{{-\odot{\underline{{{-\pi}}}}}}}\exists\mathbb{H}}\&\exists\mathbb ...

一季度亏损2093万元 今年一季度，主业为珠宝首饰的ST金一实现营业收入1.44亿元，亏损2093万元，但扣非净利润为749万 元。 【导读】ST金一将自6月16日开市起撤销其他风险警示 6月12日晚，ST金一（002721）发布公告称，公司股票交易于6月13日（星期五）开市起停牌一天，并 于6月16日（星期一）开市起复牌、撤销其他风险警示，证券简称由"ST金一"变更为"金一文化"，证券 代码仍为"002721"。撤销其他风险警示后，公司股票交易的日涨跌幅限制由5%变为10%。 6月12日，ST金一股价以3.5元/股报收，最新市值为93.1亿元。 2024年，ST金一启动上市公司跨界并购优质资产的相关工作，锁定专注于金融行业应用系统软件开发 和服务的国家高新技术企业开科唯识。 2024年11月，ST金一与开科唯识达成收购意向后，聘请中介机构对标的公司进行了深入的尽职调查、 审计评估工作，并于2025年3月10日经董事会审议通过后，交易各方签署正式股份转让协议，交易双方 于2025年4月上旬办理完毕交割手续，实现公司从传统的黄金珠宝行业向软件信息领域的战略转型。 近日，王晓峰在与投资者交流时称，根据公司长期发展 ...

Core Viewpoint - The report outlines the independent financial advisory opinion regarding the major asset sale and related transactions of Wolong New Energy Group Co., Ltd, emphasizing the transaction's compliance with relevant regulations and its strategic significance for the company's future direction [1][2][3]. Summary by Sections Transaction Overview - The transaction involves the sale of 90% equity in Shanghai Mining Co., Ltd by Wolong New Energy to Zhejiang Wolong Shunyu Investment Co., Ltd for a total price of 191.11 million yuan [8][10]. - The transaction is classified as a major asset sale and constitutes a related party transaction [8][9]. Financial Assessment - The valuation of the 100% equity of Shanghai Mining is assessed at 226.90 million yuan, resulting in a 19.11 million yuan transaction price for the 90% stake, reflecting a valuation increase [8][10]. - The transaction price was adjusted due to a cash dividend of 29.39 million yuan paid by Shanghai Mining to the company prior to the sale [10]. Impact on Company Operations - Post-transaction, the company will cease its involvement in copper concentrate trading, allowing it to focus on renewable energy sectors such as solar, wind, and hydrogen storage [11][12]. - The transaction is expected to reduce the company's total assets and liabilities, with total assets decreasing from 866,248.57 million yuan to 821,705.94 million yuan, and total liabilities decreasing from 408,514.93 million yuan to 360,445.85 million yuan [13][14]. Strategic Direction - The company aims to enhance its core competitiveness and operational efficiency by reallocating resources towards high-quality renewable energy projects, aligning with national "dual carbon" policies [11][14]. - The company plans to strengthen its technological capabilities in the renewable energy sector, focusing on projects that promise sustainable growth [11][12]. Governance and Compliance - The independent financial advisor confirms that there are no conflicts of interest in the transaction and that all necessary due diligence has been conducted [2][3]. - The transaction has received preliminary approval from the company's board and requires further approvals from shareholders and regulatory bodies [15][16]. Investor Protection Measures - The company commits to strict adherence to information disclosure obligations to protect the interests of minority shareholders during the transaction process [16][17]. - Measures are in place to ensure that the transaction does not adversely affect the immediate returns for shareholders, with commitments from major stakeholders to refrain from selling shares during the transaction period [21][22].

6月11日，"麻醉一哥"人福医药（600079.SH）发布公告称，公司董事李杰先生、董事兼总裁邓霞飞 先生、副总裁李莉娥女士因到龄退休提交辞职报告。与此同时，公司聘任原副总裁杜文涛先生为新任总 裁。 公告显示，上述三人离任的原因均为到龄退休，三人将逐步从下属控股子公司职务中办理离任手 续。 人福医药管理层此番大换血并不让人意外。今年4月25日，人福医药发布公告称，其控股股东当代 科技的重整计划已获湖北省武汉市中级人民法院批准。根据重整计划，招商局创新科技（集团）有限公 司通过全资子公司招商生命科技（武汉）有限公司（招商生科），以118亿元入局，从当代科技手中接 过了人福医药。 重整计划实施完成后，招商生科合计控制人福医药3.87亿股股份，占总股本的23.7%，并享有相应 表决权。人福医药的控股股东将由当代科技变更为招商生科，实际控制人从艾路明变为招商局集团有限 公司。当时外界就预测，人福医药可能会迎来管理层变动。 不过，市场也同时预期，新股东的国资背景与产业协同能力将为人福医药带来更广阔的发展空间， 麻醉药龙头在政策壁垒与创新驱动的双重护城河下，或迎来新一轮增长周期。而招商局集团的正式入主 和高管层的洗牌，标 ...

Summary of Baxter's Conference Call Company Overview - **Company**: Baxter International Inc. - **Key Executives**: Joel Grade (CFO), Claire Trackman (SVP, Investor Relations) Core Industry Insights - **Industry**: Healthcare, specifically focusing on medical devices and pharmaceuticals Key Points and Arguments CEO Search Update - The board is making diligent progress in the CEO search, balancing speed and thoroughness [3][4] Growth Strategy - Baxter aims for a growth target of 4% to 5%, driven by innovation and R&D investments [6] - The company is focusing on operational effectiveness and streamlining processes [7] - Inorganic growth opportunities are also part of the strategy, alongside cultural integration [7] Business Identity Post-Sales - Post divestitures (BPS and Vantiv), Baxter is focusing on agility and simplification of operations [11] - The company is emphasizing innovation and capital allocation to drive growth and margin expansion [12] Q1 Performance - Q1 performance exceeded expectations, with a 5% growth driven by strong performance in HST and MPT segments [13][14] - HST grew at a rate of 7%, while frontline care grew by 5% [14] - Notable growth in pump sales and advanced surgeries, although some softness in the U.S. pharma segment [15][16] Q2 Guidance - Q2 guidance is conservative, projecting 1% to 2% growth due to expected conservation in MPT and historical seasonal trends [17][19] - The second quarter is typically the weakest, and hospitals are adjusting back to normal ordering patterns post-allocation [21][24] Pricing Dynamics - Pricing improvements are anticipated, with a full benefit expected in Q2, contributing to a projected 100 basis points improvement for the year [30][31] - The impact of tariffs is being monitored, with China being a significant factor in tariff-related costs [46][47] Margin Expectations - Full-year margin guidance is set at 16% to 16.5%, with expectations for gradual improvement as cost initiatives ramp up [49][52] - TSA income and stranded costs are influencing gross margins, with a focus on operating margins for a clearer profitability picture [65][76] Balance Sheet and Cash Utilization - Baxter is on track to achieve a net debt to EBITDA ratio of three times by year-end, allowing for potential stock buybacks and tuck-in acquisitions [77][78] Additional Important Insights - The company is focusing on maintaining a balanced view across its product lines, particularly in MPT and HST segments [39][42] - There is a recognition of the need for hospitals to return to historical purchasing habits, which may take time [24][28] - The company is committed to exploring small-scale M&A opportunities to enhance growth [78] This summary encapsulates the key insights and strategic directions discussed during Baxter's conference call, highlighting the company's focus on growth, operational efficiency, and financial health.

Summary of LifeStance Health Group (LFST) FY Conference Call - June 10, 2025 Company Overview - LifeStance Health Group is a leader in outpatient mental health services with approximately 7,500 clinicians and over 8 million visits annually across 550 locations in 33 states [4][5][6]. Core Strategies and Management Transition - The management transition from Ken Burdick to Dave Borden as CEO and Ryan McGordy as CFO is expected to be seamless, with a continued focus on clinical and operational excellence [3][9]. - The company aims to maintain a strategy centered on profitable growth, disciplined capital deployment, and enhancing patient and clinician experiences [7][12]. Operational Milestones - Key operational milestones include the rollout of a consistent operating model, a digital patient check-in tool, and improvements in cash collections leading to a positive free cash flow of over $85 million [13][14]. - The company achieved double-digit adjusted EBITDA margins and positive net income for the first time in Q1 2025 [14]. Growth and Hiring Strategy - The clinician base grew by 17% in 2023, with a focus on filling existing clinician schedules rather than solely organic hiring [20][22]. - The company plans to maintain low double-digit clinician growth to support mid-teens revenue growth targets [27][29]. Retention and Competitive Landscape - Despite stable turnover rates, the company is implementing initiatives to improve clinician retention, including changes to payroll frequency and the introduction of cash-based productivity bonuses [34][36]. - LifeStance continues to attract new clinicians, particularly those seeking W-2 benefits and flexible working conditions [40][42]. Financial Performance and Projections - The company anticipates low to mid-single-digit rate increases from payers, with expectations for continued growth in revenue per visit [46][50]. - LifeStance aims for mid-thirties gross margins and 15-20% EBITDA margins in the long term, driven by operational efficiencies and leveraging G&A costs [78][80]. Investment in Technology and Infrastructure - The company is in the early stages of evaluating EHR solutions to enhance clinician and patient experiences, with a decision expected by the end of 2025 [75][76]. - Investments in technology and operational efficiencies are seen as critical for future growth and margin expansion [72][69]. Conclusion - LifeStance Health Group is positioned for continued growth in the outpatient mental health sector, with a strong focus on operational excellence, clinician retention, and strategic investments in technology and infrastructure to support long-term profitability [44][80].